Ozempic, Wegovy, Mounjaro: What the Longevity Data Actually Says

GLP-1 receptor agonists are the most consequential drug class of the decade. The weight loss data is well known. The longevity, cardiovascular, cognitive, and lifespan implications are not.

The SELECT trial showed a 19% reduction in all-cause mortality in semaglutide users. That is not a weight loss outcome. That is a longevity outcome — and it is being underreported in mainstream coverage.

This report covers:

• Cardiovascular outcomes — SELECT, LEADER, REWIND trials broken down
• Cognitive and neurological data — the Alzheimer's and Parkinson's signal
• All-cause mortality data — the most important number nobody is talking about
• The risk profile — muscle loss, pancreatitis, rebound weight gain scored honestly
• Who should consider GLP-1s for longevity — and who should wait
• The difference between weight loss evidence and longevity evidence

Every outcome scored: Start / Stop / Wait / Avoid.

Prescription medication context. Not medical advice. Consult your physician.

No affiliates. No sponsors. Human trials only.